Bloks Group Ltd., the popular maker of Ultraman and Transformers figurines, raised HK$1.67 billion ($215 million) in Hong ...
Biotech firm Maze Therapeutics, backed by Third Rock Ventures, revealed a profit for the first nine months of 2024 in its ...
The restaurant group announced Tuesday that Jose Alberto Dueñas is stepping down. Chief financial officer Paul Carbone, a ...
Spanish travel technology firm HBX Group is considering announcing plans for an initial public offering as early as next week ...
(Reuters) -Oilfield services provider Flowco Holdings on Tuesday said it is seeking a valuation of up to $2 billion in its ...
Southland Corporation, the Dallas-based operator of 7-Eleven then facing rumours of a Canadian takeover attempt, announced ...
Once the allotment of Fabtech Technologies IPO shares is finalised, investors who applied for the offering can check the ...
Just a month after announcing a $115 million series D financing to advance its lead assets, Maze Therapeutics is looking to ...
The Standard Glass Lining IPO, having a price band of ₹133-140 per share, aims to raise ₹410.05 crore. The issue was ...
Drug developer Maze Therapeutics Inc.'s rollercoaster ride is leading to the Bay Area's first biotech IPO filing of 2025.
While institutional demand from qualified buyers has been tepid, the grey market is buzzing with a premium of around 69%, hinting at strong listing gains when the shares make their debut on January 14 ...